Showing results (91-100 of 162) with videos related to
Sort By:
Pageof 17
Blood Advances|April 4, 2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemiaPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.Leukemia|October 20, 2019
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 studyJan A Burger, Paul M Barr, Tadeusz Robak, et al.The New England Journal of Medicine|June 2, 2018
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's MacroglobulinemiaMeletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2023
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic LeukemiaJohn N Allan, Ian W Flinn, Tanya Siddiqi, et al.Future Oncology (London, England)|January 9, 2023
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language SummaryPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.Future Oncology (London, England)|July 29, 2024
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trialAlessandra Tedeschi, Constantine S Tam, Roger G Owen, et al.The Lancet. Oncology|December 8, 2018
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.American Journal of Hematology|February 16, 2019
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysisSusan M O'Brien, John C Byrd, Peter Hillmen, et al.Blood Advances|December 3, 2024
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemiaBenjamin M Heyman, Stephen S Opat, Björn E Wahlin, et al.Blood|December 8, 2018
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter studyJorge J Castillo, Gilad Itchaki, Jonas Paludo, et al.Pageof 17